Puma Biotechnology Inc (NASDAQ:PBYI) saw unusually large options trading on Friday. Stock investors purchased 7,131 call options on the company. This represents an increase of approximately Infinity compared to the average volume of 0 call options.

Puma Biotechnology (PBYI) opened at $100.20 on Wednesday. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same period last year, the business posted ($1.11) earnings per share.

In related news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $120.00, for a total value of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares in the company, valued at $5,068,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Strs Ohio bought a new position in shares of Puma Biotechnology during the second quarter valued at about $122,000. Cubist Systematic Strategies LLC bought a new stake in shares of Puma Biotechnology in the second quarter worth about $146,000. Sei Investments Co. bought a new stake in shares of Puma Biotechnology in the third quarter worth about $256,000. Kazazian Asset Management LLC bought a new stake in shares of Puma Biotechnology in the second quarter worth about $209,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Puma Biotechnology in the second quarter worth about $211,000. 80.98% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently commented on PBYI. BidaskClub cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Citigroup Inc. increased their target price on Puma Biotechnology from $156.00 to $164.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Stifel Nicolaus reissued a “buy” rating and issued a $110.00 target price (down previously from $118.00) on shares of Puma Biotechnology in a research note on Thursday, August 10th. J P Morgan Chase & Co set a $105.00 target price on Puma Biotechnology and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Barclays PLC reissued a “buy” rating and issued a $122.00 target price (up previously from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $130.67.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/puma-biotechnology-sees-unusually-large-options-volume-pbyi/1703629.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.